Patricia Inacio, PhD,  science writer—

Researchers at Johns Hopkins University in Baltimore presented key findings today, Feb. 19, concerning the presence of contrast-enhancing lesions in later stages in the relapsing-remitting experimental autoimmune encephalitis (EAE) model. The presentation was made at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, which is ongoing through…

At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016, being held from Feb. 18–20 in New Orleans, LA, researchers have gathered to discuss “Progressive MS: Bench to Bedside and Back,” the meeting’s theme. Secondary progressive multiple sclerosis (SPMS) is one of four types of MS, and is…

The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC), responsible for assessing and monitoring safety issues for human medicines, completed a review on the risk for progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with the medicine Tysabri (natalizumab). The issued guidelines have the objective of minimizing patients’ risk.

A new campaign called “End our pain” is asking people to sign a petition calling on the U.K. to allow all patients with multiple sclerosis (MS) there to have access to medical cannabis as a treatment for MS symptoms, in keeping with countries  such as Canada and Germany, and a number…

In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the drug natalizumab (Tysabri) could lead to a tenfold increase in the levels of blood antibodies associated with a virus causing a rare but severe brain disease known as progressive multifocal…

Multiple sclerosis (MS) patients treated with natalizumab have an increased risk of developing high levels of antibodies associated with a virus causing a rare, but often fatal, brain infection known as progressive multifocal leukoencephalopathy (PML), researchers reported. Their study, “Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values,”…

A team of researchers recently discovered two novel multiple sclerosis (MS)-associated genes that are regulated by vitamin D levels. The study, titled “The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells,” was published in the advanced online section of …

A new source of stem cells, the mesenchymal stem cells (MSCs) isolated from the human periodontal ligament (hPDLSCs), offers a potential treatment capable of halting multiple sclerosis (MS) progression. The study, “Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis,” was published…

In a recent study, a team of researchers argued that, contrary to what has been proposed, subclinical Bordetella pertussis colonization is an important cause of multiple sclerosis (MS). The study, “The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis,” was published in the journal…

Researchers found that a group of untreated patients with multiple sclerosis (MS) and patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) carry a specific group of hyperactivated immune cells, the inflammatory CD8+ T cells, suggesting a potential common mechanism contributing to disease pathogenesis. The study, “A Preliminary Comparative…

A research team recently showed that key enzymes of energy metabolism pathways are differentially expressed in active and inactive multiple sclerosis (MS) lesions, and may contribute to axonal degeneration in MS. The study, titled “Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions,” was published in the…

Researchers are proposing for a first time that multiple sclerosis (MS) is triggered by the death of a specific cell population within the central nervous system called oligodendrocytes. The study, titled “Oligodendrocyte death results in immune-mediated CNS demyelination,” was published in the journal Nature Neuroscience. Oligodendrocytes,…

In a new study titled “Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines,” researchers report a correlation between an adipokine called adipsin and the pathogenesis of multiple sclerosis (MS). The study was published in the Multiple Sclerosis International journal. Obese adolescents…

In a new study entitled “Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis,” a team of researchers discovered a subgroup of secondary progressive multiple sclerosis patients (SPMS) exhibiting the same gene expression response to interferon (IFN) treatment as patients with relapsing-remitting MS…

In a recent study, researchers show how a natural antioxidant within pomegranate seeds is capable of inhibiting demyelination in a mouse model for multiple sclerosis (MS), supporting novel formulations of natural antioxidants as therapeutics for demyelinating diseases. The study, “Treatment of a multiple sclerosis animal model by a novel nano drop formulation of…

In a recent study entitled “Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice,” a team of researchers investigated whether interleukin (IL)-32, a cytokine with an established role in rheumatoid arthritis, has a protective function in a mouse model of human multiple…

In a new study entitled “Reduced cortical microvascular oxygenation in multiple sclerosis: a blinded, case-controlled study using a novel quantitative near-infrared spectroscopy method,” a team of researchers at the Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary investigated whether frequency domain near-infrared spectroscopy technology can measure the potential…

In a recent study entitled “Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination,” researchers investigated whether sulfasalazine treatment, an anti-inflammatory and immune-modulating drug, could promote remyelination of axons in an organism model of demyelination diseases such as multiple sclerosis (MS). The study was published in the…

In a new study entitled “Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis,” a team of researchers performed a comparative analysis of metabolites between control mice and a mouse model with experimental autoimmune encephalitis (EAE, the most commonly used…

In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (Gilenya, Novartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that…

In a recent study entitled “MicroRNA expression profiling of human blood monocyte subsets highlights functional differences,” a team of researchers discovered a pool of 66 microRNAs that underlie differences in phenotype and function of a group of immune cells with key roles in multiple sclerosis. The study was published…

In a new study entitled “Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation,” a team of scientists discovered the mechanism by which autoreactive T cells are capable of penetrating a patient’s brain and induce multiple sclerosis. The study was recently published in the advance online issue…

In a recent study entitled “Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis – Copaxone and Glatopa. Both of these MS therapies are glatiramer…

Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is currently being held in Barcelona, from 7 to 10 of October, 2015. As the biggest scientific event focused on Multiple Sclerosis, researchers and clinicians from around the world, with more than 8,000 participants, gather…

In a new study entitled “The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients,” a team of scientists discovered that differences in response to glatiramer acetate therapy among multiple sclerosis (MS) patients is potentially dependent on the presence of reactive brain-specific B…

In a new study entitled “LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice”, a team of scientists report that the loss of myelin in multiple sclerosis (MS) patients’ brains contributes to their cognitive impairment. They showed that inhibiting protein LINGO-1 can…

In a new study entitled “Neutrophil trails guide influenza-specific CD8+ T cells in the airways,” researchers uncovered a key mechanism mediated by neutrophils that guides immune system cells to the site of an injury or infection. Moreover, this mechanism is crucial for immune cells to function properly…

In a new study entitled “Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses,” researchers investigated how breastfeeding impacts risk for disease relapse in women with multiple sclerosis. The study was published in the journal JAMA Neurology. Around 20 to 30% of women with…

In a new study entitled “Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity,” researchers identified variations in genes coding for microRNAs that influence patients’ susceptibility to develop multiple sclerosis, as well as the disease course. Most importantly, these variations were gender specific, identified only…